226 related articles for article (PubMed ID: 22177102)
1. Emerging treatments and signaling pathway inhibitors.
Tang JY; Marghoob AA
Semin Cutan Med Surg; 2011 Dec; 30(4 Suppl):S14-8. PubMed ID: 22177102
[TBL] [Abstract][Full Text] [Related]
2. Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
Lear JT
N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909
[No Abstract] [Full Text] [Related]
3. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib in advanced basal-cell carcinoma.
Henkin RI
N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
[No Abstract] [Full Text] [Related]
5. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
Ali FR; Lear JT
Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
[TBL] [Abstract][Full Text] [Related]
6. Harnessing hedgehog for the treatment of basal cell carcinoma.
Harms KL; Dlugosz AA
JAMA Dermatol; 2013 May; 149(5):607-8. PubMed ID: 23677088
[No Abstract] [Full Text] [Related]
7. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
8. Basal cell carcinoma: hedgehog pathway inhibitors and beyond.
Walls B
Cutis; 2013 Jun; 91(6):E1-4. PubMed ID: 23837158
[No Abstract] [Full Text] [Related]
9. [Not Available].
Basset-Seguin N
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
[TBL] [Abstract][Full Text] [Related]
10. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitors of the Hedgehog signalling pathway: hope for the treatment of basal cell carcinoma].
Vidal V
Med Sci (Paris); 2010 Mar; 26(3):231-3. PubMed ID: 20346268
[No Abstract] [Full Text] [Related]
12. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with Hedgehog pathway inhibitors.
Low JA; de Sauvage FJ
J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma.
Tang JY
Semin Cutan Med Surg; 2011 Dec; 30(4 Suppl):S6-9. PubMed ID: 22177103
[TBL] [Abstract][Full Text] [Related]
15. Hedgehog pathway inhibition and the race against tumor evolution.
Atwood SX; Chang AL; Oro AE
J Cell Biol; 2012 Oct; 199(2):193-7. PubMed ID: 23071148
[TBL] [Abstract][Full Text] [Related]
16. Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.
Mohan SV; Chang AL
Semin Cutan Med Surg; 2014 Jun; 33(2):68-71. PubMed ID: 25085664
[TBL] [Abstract][Full Text] [Related]
17. Vismodegib.
Meiss F; Zeiser R
Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
[TBL] [Abstract][Full Text] [Related]
19. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
Wolfe CM; Green WH; Cognetta AB; Hatfield HK
Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
[No Abstract] [Full Text] [Related]
20. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.
Abidi A
Indian J Pharmacol; 2014; 46(1):3-12. PubMed ID: 24550577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
